Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Portable flanking sequences modulate CTL epitope processing
Sylvie Le Gall, … , Pamela Stamegna, Bruce D. Walker
Sylvie Le Gall, … , Pamela Stamegna, Bruce D. Walker
Published November 1, 2007
Citation Information: J Clin Invest. 2007;117(11):3563-3575. https://doi.org/10.1172/JCI32047.
View: Text | PDF
Technical Advance

Portable flanking sequences modulate CTL epitope processing

  • Text
  • PDF
Abstract

Peptide presentation is critical for immune recognition of pathogen-infected cells by CD8+ T lymphocytes. Although a limited number of immunodominant peptide epitopes are consistently observed in diseases such as HIV-1 infection, the relationship between immunodominance and antigen processing in humans is largely unknown. Here, we have demonstrated that endogenous processing and presentation of a human immunodominant HIV-1 epitope is more efficient than that of a subdominant epitope. Furthermore, we have shown that the regions flanking the immunodominant epitope constitute a portable motif that increases the production and antigenicity of otherwise subdominant epitopes. We used a novel in vitro degradation assay involving cytosolic extracts as well as endogenous intracellular processing assays to examine 2 well-characterized HIV-1 Gag overlapping epitopes presented by the same HLA class I allele, one of which is consistently immunodominant and the other subdominant in infected persons. The kinetics and products of degradation of HIV-1 Gag favored the production of peptides encompassing the immunodominant epitope and destruction of the subdominant one. Notably, cytosolic digestion experiments revealed flanking residues proximal to the immunodominant epitope that increased the production and antigenicity of otherwise subdominant epitopes. Furthermore, specific point mutations in these portable flanking sequences modulated the production and antigenicity of epitopes. Such portable epitope processing determinants provide what we believe is a novel approach to optimizing CTL responses elicited by vaccine vectors.

Authors

Sylvie Le Gall, Pamela Stamegna, Bruce D. Walker

×

Figure 1

The endogenous processing of an immunodominant Gag epitope is more efficient than that of subdominant epitopes.

Options: View larger image (or click on image) Download as PowerPoint
The endogenous processing of an immunodominant Gag epitope is more effic...
(A) HLA-A3 HeLa cells were pulsed with decreasing amounts of p17 Gag immunodominant RK9 (squares) or p17 Gag subdominant KK9 (triangles) and used as targets in a 51Cr release assay with RK9- or KK9-specific CTLs respectively. (B) HLA-A3 HeLa cells transfected with a CMV-driven HIV-1 LAV p17 expression vector (schemed above the graph) were used as targets in a 51Cr assay with RK9- (black bars) or KK9-specific (gray bars) CTLs. The recognition of endogenously processed RK9 and KK9 epitopes by specific CTLs (left side) was compared with that of transfected cells pulsed with 0.1 μM RK9 or KK9 peptides (right side). (C) p17 immunodominant RK9 (squares) and RT subdominant ATK9 (circles) peptide titration on HeLa-A3 cells. (D) HLA-A3 HeLa cells transfected with a CMV-driven vector expressing a HIV-1 LAV RT fragment (HXB2 residues 153–560) with a C terminal p17 sequence (5-RK9-3; according to the position of RK9) (schemed above the graph) were used as targets in a 51Cr assay with RK9- (black bars) or ATK9-specific (gray bars) CTLs. The recognition of endogenously processed RK9 and ATK9 epitopes by specific CTLs (left side) was compared with that of transfected cells pulsed with 0.1 μM RK9 or ATK9 peptides (right side). Lysis of cells without peptides or with mismatched peptides was below 3%. All data represent averages of 3 experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts